Research & Development
Clinical trial planned for COVID-19 rapid breath test
The investigational BreathTest-1000 mass spectrometer is being positioned as a noninvasive, self-administered test of breath samples for various COVID-19 strains. The developers envisage that relative to the gold standard for COVID-19 detection, polymerase chain reaction (PCR) tests, their product would be a lower-cost, more convenient option suitable for wide distribution.
October 20, 2020
Is whole genome sequencing for children with rare diseases worth the price?
WGS has been proposed as a possible shortcut out of the "diagnostic odyssey," the ordeal endured by patients with rare diseases as they undergo a seemingly endless series of clinical evaluations, imaging studies, and laboratory tests before obtaining a diagnosis.
June 29, 2020
Diagnostics wanted for emerging infections, tomorrow's pandemics
In a 2018 global IVD market report, Kalorama Information lead analyst Shara Rosen wrote that the dark side of globalism is the spread of unwanted conditions. There are many examples of previously unknown or rare pathogens that spread and became a major problem globally -- this can happen rapidly with people traveling by air throughout the world, Rosen noted.
June 18, 2020
Smartphones double as point-of-care diagnostics
The technical capabilities of these phones have become so advanced that they can compete with technology once thought to be only the domain of physicians' offices and hospitals. Research groups and startup companies are developing apps and technology that turn smartphones into tools that can diagnose eye disease, perform home-based urinalysis, diagnose ear infections and respiratory disease, and help women learn about their reproductive health.
December 1, 2019
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
Page 1 of 1